Von Willebrand Factor in Liver Cirrhosis Study
Part of Digestive system clinical trials.
This study looks at a blood clotting factor (von Willebrand factor) in people with liver cirrhosis and high blood pressure in the liver. It may help doctors understand how liver disease affects your bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You have been diagnosed with liver cirrhosis (any stage, even if you don't have symptoms).
- You do not have a sudden or recent liver problem (like an acute infection).
- You do not have a current infection (including in the belly fluid).
- You do not have active cancer outside the liver.
- You have not had a liver transplant before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study looks at how clotting measurements relate to bleeding risk in people with liver cirrhosis who need a planned liver procedure. The study may help doctors understand what coagulation results mean when doing these procedures safely.
This study tracks people with liver cirrhosis to see how often portal vein thrombosis (a blood clot in the main vein to the liver) occurs and how it can be treated with blood thinners. It aims to improve care for those at risk of these clots.
This trial is for people with liver cirrhosis who have high blood pressure in the vein that carries blood to the liver (portal hypertension). It uses a special ultrasound with contrast to learn more about the condition.
This study looks at special cells from blood vessels (endothelial colony-forming cells) in people with von Willebrand disease (a bleeding disorder) or a related acquired condition. The goal is to better understand these conditions using blood donations.
This study looks at cardiovascular problems and blood-clot events (like deep vein clots or pulmonary embolism) in adults with Von Willebrand disease in western France. It may help doctors better understand who is at risk and how to manage these complications.
This Phase 1/2 study tests VGA039 in healthy adults and people with von Willebrand disease (VWD). The goal is to see if the drug is safe and how it affects bleeding-related factors, especially in people who have symptoms.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.